1. Replimune faces a class action lawsuit for securities fraud. 2. Allegations relate to false statements regarding the IGNYTE trial. 3. Lawsuit affects investors from November 2024 to July 2025. 4. Investors can participate without out-of-pocket costs. 5. Deadline to request lead plaintiff status is September 22, 2025.
Class action lawsuits often induce negative sentiment and could lead to sell-offs, similar to what happened with other biotech firms facing litigation. Historical cases, such as those involving Mimivax Inc. and early-stage trials, show that investor confidence erodes if results are misrepresented.
The lawsuit raises serious concerns about Replimune's credibility and financial health, likely to deter new investors while spurring current shareholder anxiety about future earnings and operational stability.
Immediate impact expected as news circulates and investors react to potential legal ramifications, reminiscent of how similar announcements have historically affected biopharma stocks shortly after they become public.
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ:REPL) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=163440&wire=4
REPL investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT'S NEXT? If you suffered a loss in Replimune Group, Inc. during the relevant time frame, you have until September 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/replimune-group-inc-sued-for-securities-law-violations--investors-should-contact-levi--korsinsky-before-september-22-2025-to-discuss-your-rights--repl-302538411.html
SOURCE Levi & Korsinsky, LLP